摘要
本研究采用噬菌体表面显示技术克隆抗CD20抗体轻、重链可变区基因，构建嵌合抗CD20抗体及其Fab'片段，在哺乳动物细胞和大肠杆菌中进行表达；并对Fab'抗体片段的体内外抗瘤活性进行研究，以期将抗CD20抗体HI47推向B淋巴细胞瘤临床治疗应用。
一 轻重链可变区基因克隆及单链抗体库的构建
常规提取HI47杂交瘤细胞总RNA，利用RT-PCR法扩增抗体轻重链可变区基因片段，经Overlap PCR，利用连接链(G_4S)_3基因片段将抗体轻重链基因连接构成单链抗体(ScFv)基因，将ScFv基因重组到pCANTAB 5E载体上，构建抗CD20单链抗体噬菌体文库(约3×10~6克隆)，以表达CD20分子的Daudi细胞为靶抗原，经Panning，ELISA法筛选，获得多个具有CD20结合活性的克隆，对克隆6的基因序列进行序列测定分析，结果显示克隆6的基因序列完符合PDB文库中的抗体基本框架序列，是抗体基因序列。
二 嵌合抗体的构建表达及活性鉴定
利用PCR从表达载体pCANTAB 5Ecd20ScFv上扩增抗CD20抗体轻重链可变区基因，将VH、VL基因克隆到表达载体pYZF中，构建抗CD20抗体表达载体pYZFcd20，并在大肠杆菌中进行高效可溶性分泌表达Fab'，表达量可达3mg／ml。
本研究对嵌合抗CD20 Fab'片段的体内外活性进行了进一步的研究，竞争性免疫荧光抑制试验结果显示，Fab'特异结合Daudi细胞表面CD20，MTT法测定结果表明，Fab'表达产物抑制Daudi细胞、Raji细胞的生长，IC_(50)分别为69μg／ml、26μg／ml。~3H掺入试验显示，嵌合抗CD20 Fab'不抑制Daudi细胞、Raji细胞DNA合成，但对RNA合成具有抑制作用。以50mg／kg剂量，四天一
To make monoclonal antibody HI47 enter the clinic therapy of B cell lymphoma, genes of variable region of HI47 were cloned by phage display technology, chimeric antibody was constructed to low HAMA of HI47 and expressed in mammalian cell and Ecoli.
1 Cloning of antibody variable region genes and construction of anti-CD20 ScFv phage display library
Extract total RNA of HI47 hybridoma cell, amplify the genes of antibody variable region of heave chain(VH) and light chain(VL) by RT-PCR, VH and VL were linked by overlap PCR with (G_4S)_3 linker to construct ScFv, ScFv was then cloned into the vector pCANTAB 5E to construct the anti-CD20 ScFv phage display library, through panning, screening by ELISA with Daudi cell as target cell and getting several clones binding specially to CD20, result from the DNA sequencing of clone 6 indicated that this sequence is an antibody gene sequence.
2 Construction, expression and function study of chimeric anti-CD20 antibody
Amplified genes of VH and VL of HI47 from the anti-CD20 ScFv expression vector pCANTAB5Ecd20 by PCR, then cloned VH and VL into the vector pYZF containing human antibody CH1 and CL to construct Fab' expression vector pYZFcd20, transformed 16C9 with pYZFcd20 and expressed Fab' in 16C9, The yield of Fab' in 16C9 is about 3mg/ml.
Bioactivities of Fab' was studied in vivo and vitro. competitive inhibition of immune fluorescence experiment show that the Fab' inhibits the binding of monoclonal antibody HI47 to CD20 on the surface of Raji cell. Growth inhibition of Daudi and Raji cell by Fab' were observed by MTT method. Fab' inhibited the synthesis of RNA but not DNA of Daudi cell and Raji cell. Experimental therapy of Raji cell lymphoma in dose of 50mg/kg, every four days once, 6 times in a nude mouse xenograft model of Raji cell showed that Fab' has a good anti-tumor effect on Raji cell lymphoma, the tumor growth inhibition rate is about 56%. Induction of tumor cell apoptosis maybe one of anti-tumor mechanisms of chimeric anti-CD20 Fab' antibody fragment .
VH and VL genes were cloned into pDR2 containing human antibody CH1,
引文
1 Leget GA, Czuczman MS: Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998,10: 548-551
2 Goldenberg MM: Trastuzumab,a recombinant DNA-derived humanized monoclonal antibody,a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999, 21: 309-318
3 Vitetta ES, Stone M, Amlot P et al. Phase immunotoxin trial in patients with B cell lymphoma. Cancer Ress 1991, 51:4052
4 Grossbard ML, Freedman AS, Ritz J et al. Serotherapy of B cell lymphoma with anti-B4-blocked ricin:A phase I trial of daily bolus infusion. Blood 1992, 79: 576
5 Grossbard ML, Freedman AS, Kinsella JM et al. Immunjotherapy with anti-B4- blocked ricin (anti-B4-bR): Phase I trials of continuous infusion in patients with B cell neoplasms. Blood 1991,78: 174a(abstr. Suppl)
6 grossbard ML, Gribben JG, Freedman AS et al. Adjuvant immunotherapy with anti-B4-blocked ricin following autologous bone marrow transplantation (ABMT) for B cell non-Hodgkin's lymphoma. Blood 1991, 78: 234a(abstr. Suppl)
7 Hertler AA, Schlossman DM, Borowitz MJ et al. An anti-CD5 immunotoxin for chronic lymphocytic leukemian:Enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer 1989,43: 215
8 Lemaistre F, Rosenblum M, Reuben J et al. Phase I study of genetically engineered DAB486 IL-2 in IL-2receptor expressing malignancies. Blood 1990, 76: 360a, (abstr. Suppl)
9 Schwartz G, Tepler I, Charette J et al. Complete response of a Hodgkin's lymphoma in phase I trial of DAB486 IL-2,an IL-2-diphtheria fusion toxin. Blood 1991, 78:175a(abstr. suppl)
10 Naddler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147
11 Brown SL, Miller RA, Horning SJ et al. Treatment of B cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989, 73: 651
12 Hale G, Dyer MJS, Clark MR et al. Remission induction in non-hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988, 2: 1394
13 Dyer MJS, Hale G, Hayhoe FGJ et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989, 73:1431
14 Scheinberg DA, Straus DJ, Yehsd Divgi C et al. A phase I toxincity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol 1990, 8: 792
15 Press OW Pros[erts for the managment of non-Hodgkin' s lymphomas withmonoclond antibodies and immunoconjugates Cancer J Sci Am 1998; 4(supp12): S19-26
16 Press OW, Appelbaum F, Ledbetter JA, Martin PJ et al. Monoclonal antibody 1F5(Anti-CD20) serptherapy of human B cell lymphomas. Blood 1987, 69: 584-91
17 Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating dingle-dose infusion of chimeric anti-CD20 monoclonal antibody(IDECC2B8) in patients with recurrent B cll lymphoma. Blood 1994, 84: 2457-66
18 Maloney DG, Gdllo-Lopez AJ, Bodkin DJ et al. IDEC-C2BS: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15: 3266-74
19 Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2BS(Rituxan) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hldgkin's lymphoma. Blood 1997, 90: 2188-95
20 McLaughlin P., Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: halg\f of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16: 2825-33
21 Coiffier B, Haioun C, Ketterer N et al. Rituximab(anti-CD20 monoclonal antibody) for the treatment of patents with relapsing or refractory aggressive lymphloma: a multicenter phase Ⅱ study. Blood 1998, 92: 1927-32
22 Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with olw grade B cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17: 268-76
23 Nguyen DT, Amess JA, Doughty H et al. IDEC-C2BS(Rituxan) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999, 62: 76-82
24 Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support[comments]/ M Emg; K, ed 1993, 329: 1219-24
25 Press OW, Eary JF, Appelbaum FR et al. Phase Ⅱ trial of 131 I-B1(anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancer 1995, 346: 336-40
26 Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B cell lymphoma. J Clin Oncol 1996, 14: 1974-81
27 Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunjotherapy of B cell lymphoma with I-131 anti-B1(anti-CD20) antibody. N Engl J Med 1993, 329: 459-65
28 Knox aj, Gods ML, Trisler K et al. Yttrium -90-labeled ant-CD20 monoclonal antibody therapy of recurrent B cell lymphoma. Clin Cancer Res 1996, 2: 457-70
29 Kaminski MS, Gribbin T, Estes J et al. I-131 anti-B1 antibody for prevoiusly untreated follicular lymphoma: clinical and molecular remissions[abstract ]. Am Soc Clin Oncol Proc 1998, 17: 2
30 Witzig T, White C, Wiseman G, Gordon L et al. IDEC-Y2B8??radioimmunotherapy: responses in patients with splienomegaly [abstract]. Blood 1998, 92: 417
31 Tedder TF, Streuli M, Schlossman SF et al. Isolation and structure of a cDNA encoding the B1(CD20) cell-surface antigen of human B lympho cytes. Pro. Natl. Acad. Sci USA 1988; 85: 208-12
32 Einfeld DA, Brown JP, Valentine MA et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J1988; 7: 711-7
33 Starnenkovix I, Seed B. et al. Analysis of two cDNA clones encoding the B lympocyte antigen CD20(B1, Bp35). a type Ⅲ intergral membrane protein. J Exp. Med 1988; 167: 1975-80
34 Golay JT, Clark EA, Beverley PC, et al. The CD_(20)(Bp35) antigen is involved in activation of B cell from the G_0 to theG_1 phase of the cell cycle. J Immunol. 1985; 135: 3795
35 Stashenko p., Nsdler LM, Hardy R, et al. J. Immun. 1980; 125: 1678-1685
36 Nadler LM, Karsmeyer SJ, Anderson KC, et al. J. Clin. Invest. 1984; 74: 332-340
37 Stashenko p., Nsdler LM, Hardy R, et al. Proc. Natl. Acad. Sci. USA 1981; 78: 3848-3852
38 Rosenthal P, Rimm IJ, Umiel T, et al. J. Immunol. 1983; 131: 232-237
39 Liu AY, Robinson R Jr, Murvay ED, et al. Production of a mouse-human chimeric monoclonal antibody to CD_(20) with potent Fc-dependent biologic activity. J. Immunol. 1987; 139: 3521
40 Press OW, Farr AG, Borroz KI et al. Endocytosis and degradation of monoclonal antibodies targeting humen B-cell malignancies. Cancer Res 1989; 49: 4906-12
41 Press OW, Howell-Clark J, Andereson S et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 1390-7
42 Sweetenham J, Hieke K, Kerrigan M et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B cell nonHodgkin's lymphoma in the UK. Br J Haematol 1999 Jul, 106(1): 47-54
43 杨希峰、沈得诚、金宇光等。HI_(47)：一种抗成熟B细胞单克隆抗体制备、鉴定及其生物学特性研究；上海免疫学杂志，1990：10(2)：65-68
44 杨希峰、沈得诚、陈璋等。HI_(47)(CD_(20))单克隆抗体对B细胞活化增殖的影响；中国免疫学杂志，1991：7(1)：21-24
45 《分子克隆实验操作指南》(第二版) J．Sambrook，E．F．Fritsch，T．Maniatis等编著，金冬雁等译。，科学出版社，1992年。
46 《现代实验血液学研究方法与技术》，郑德先等主编，北京，北医大和协和医大联合出版社，1999。
47 Chung CT, Miller RH. A rapid and convenient method competent bacterial cells. Nucleic Acids Research 1988, 16(8): 3580
48 《现代分子生物学实验技术》 卢圣栋 主编，高等教育出版社，1993年7??月第一版
49 《生物医学示踪技术》王浩丹 主编，人民卫生出版社，1995年12月第一版
50 《现代药理实验方法》 张均田主编，北京医科大学中国协和医科大学联合出版社，1998年10月第一版
51 Fried J, Perez G, Clarkson BD et al. Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures: Some pitfalls in staining and data analysis. J Histchem Cytochem 1978, 26: 921
52 Zhu Z, Lu D, Kotanides H et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human edothelial cells by a chimeric anti-kinase insert domain-contianing receptor antibody. Cancer Letter 1999, 136: 203-213
53 Ward ES, Guddow D, Griffiths AD et al. Binding activities of a repertoire of dingle immunoglobulin variable domains secreted from Escherichian coli. Nature 1989, 341: 544
54 Rouddgues ML, Shalaby MR, Werther W et al. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells. Int. J. Cancer Suppl. 1992; 7: 45
55 Carter P, Kelley RF, Roudrigues ML et al. High level Escherichia Coli expression and production of bivalent humanized antibody fragment. Bio Technology 1992; 10: 163
56 Rodrigues ML, Snedecor B, Chen C et al. Engineering Fab fragments for efficient F(ab')2 formation in Escherichia coli and for improved in vivo stability. J Immunol 1993; 151(12): 6954-6961
57 Duenas M, Vazquez J, Ayala M, et al. Intra- and extracellular expression of an seFv antibody fragment in E. coli: effect of bacterial strains and pathway engineering using GroES/L chaperonins. Biotechniques 1994, 16(3): 476-7, 480-483.
58 《抗CD3单克隆抗体基因的克隆及其单链抗体表达载体的构建、表达和突变研究》许元富，中国协和医科大学 中国医学科学院硕士研究生毕业论文。
59 Knappik A, Pluckthun A et al. Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng 1995, 8: 81
60 Eldin P, Pauza ME, Hieda Y et al. High-level secretion of two antibody single chain Fv fragments by Pichia pastoris. J Immunol Methods 1997, 201: 67
61 Ridder R, Schmitz R, Legay F et al. Generation of rabbit monoclonal antibody fragments from a combinatotrial phage display library and their production in the yeast Pichia pastors. Biotechnology 1995, 13: 255
62 Rowlinson-Busza G, Deonarain MP, Epetos AA et al. Comparision of intact monoclonal antibody, it s F(Fab')2 and Fab fragment and recombinant single chain Fv in a human tumor xenograft model. Tumor Targeting 1996; 2: 37-48
63 Tedder TF, Engel P et al. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today 1994, 15(9): 450-454
64 Transfection of the CD_(20) cell surface molecule into Ectopic cell types Generates a Ca~(2+)conductance Found Constitutively in B Lymphocytes. J. cell Biol.l993,121(5):l 121-1132
65 Daming Shan, Jeffrey A Ledhetter, Press OW et al. Apoptosis of malignane human B cell by ligation of CD20 with monoclonal antibodies. Blood 1998; 91(5): 1644-1652
66 Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Radiopharmaceuticals 1997 12(3): 177 C186.
67
1 Kohler G, Milstein. Continuous culturs of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495
2 Orlandi R, Gussow DH, Jones PT et al. Cloning immunoglobulin variable domains for wxpression by the polymrease chain reaction. Proc. Natl. Acad. Sci. USA 1989; 86: 3833-37
3 Gavilondo-conley JV, Colma M, Vazquez J et al. Specific amplification of rearranged immunoglobulin variable region genes from mouse hybridoma cells. Hybridoma 1990; 9: 407-417
4 Larrick JW, Danielsson L, Brenner et al. Polymerase chain reaction using mixed palmers: cloning of human monoclonal antibody variable region genes from single hybfidoma cells. Bio/Technology 1989; 7: 934-938
5 Roudrigues ML, Shalaby MR, Werther W et al. Engineering a humanized bispeeifie F(ab')2 fragment for improved binding to T cells. Int. J. Cancer Suppl. 992; 7: 45
6 Carter P, Kelley RF, Roudrigues ML et al. High level Escherichia Coli expression and production of bivalent humanized antibody fragment. Bio Technology 1992; 10: 163
7 Rodrigues ML, Snedecor B, Chen C et al. Engineering Fab fragments for efficient F(ab)2 formation in Eschedchia coli and for improved in vivo stability. J Immunol 1993; 151(12): 6954-6961
8 赖增祖，熊冬生，杨纯正等。嵌合抗CD20抗体Fab′片段在大肠杆菌中高效表达。高技术通讯；(in pressed)
9 Rowlinson-Busza G, Deonarain MP, Epetos AA et al. Compadsion of intact monoelonal antibody, it' s F(ab)2 and Fab fragment and recombinant single chain??Fv in a human tumor xenograft model. Tumor Targeting 1996; 2: 37-48
10 Ghetie MA, Podar EM, Ilgen A et al. Homodimeriation of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrst or apoptosis of tumor cels. Pro Natl Acad Sci USA. 1997; 94: 7509-7514
11 Colcher D, Pavlinkova G, Beresford G et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Q J Nucl Med 1998; 42: 225-241
12 Dall' Acqua W, Carter P. Antibody engineering. Curr Opin Struct Biol 1998; 8: 443-450
13 Atwell J, Breheney KA, Lanrence LJ et al. ScFv multimers: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 1999; 12: 597-604
14 Legall F, Kipriyanov SM, Moldenhower G et al. Td-and tetrameric single chain Fv anribody fragments against human CD19: effect of valency on binding. FEBS Lett 1999; 45: 164-168
15 Merchart AM, Zhu Z., Yuan JQ et al. An efficient route to human bispecific Ig G. Nat Bioteehnol 1998; 16: 677-681
16 Haisma HI, Semee MF, Hooijberg E et al. Construction and Characterization of a fusion protein of single-chain anti-CD20 antibody and human b-Glucuronidase for antibody-directed enzyme prodrug therapy. Blood 1998; 92(1): 184-190
17 Mezzanzanica D, Canevari S, Mazzoni A et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity of T cells. Cancer Gene Ther 1998; 5: 401-407
18 Melani C, Figini M, Nicosia D et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 1998; 58: 4146-4154
19 Peng LS, Penichet ML, Morrison SL et al. A single - chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999; 163: 250-258
20 Timmerman JM, Levy R et al. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med 1999; 50: 507-529
21 Tdpathi PK, Qin H, Deng S et al. Antigen mimicry by an anti-idiotype antibody single chain variable fragment. Mol Immunol 1998; 35: 853-863.
22 Marks JD, Hoogenboom HR, Bonnert TP et al. J Mol Biol 1991; 222: 281-97
23 Chang CN, Landolfi NF, Queen C. J Immunol1991; 147: 3610-4
24 Bdnkmann U, Chowdhury PS, Roscoe DM et al. J Immunol Methods 1995; 182: 41-50
25 Holligen P, Prospero T, Winter G et al. Proc Natl Acad Sci USA 1993; 90: 6444-8
26 Mattheakis LC, Bhatt RR, Dower WJ et al. An intro polydisplay system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994; 91: 9022
27 Hanes J, Jermutus L, Weber-Bornhauser et al. Ribosome display efficiently??selects and evolves high-affinity antibodies in vitro from immune liraries. Proc Natl Acad Sci USA 1998; 95: 14130
28 Daugherey PS, Chert G, Olsen MJ et al. Antibody affinity maturation using bacterial surface display. Protein Eng 1998; 11: 825-829
29 Vera R, Boleti E, Greorge AJT et al. Antibody engineering: comparision of bacterial, Yeast, insect and mammalian expression systems. J Immunol Methods. 1998; 216: 165-181
30 Leget GA, Czuczman MS et al. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-551
31 Goldenberg MM. Trastuzumab: a recombinant DNA-derived humanized monoclona antibody, a novel agent for th treatment of meastatic breast cancer. Clin Ther 1999; 21: 309-3181 Chothia C, Lesk AM, Tramontano A, et al. Conformation of immunoglobulin hypervariable regions.Nature, 1989;342:877-883
2 Padlan EA, et al. Anatomy of antibody molecule. Mol Immunol, 1994;31 (3):169-217
3 Hodges RS, Heaton RJ, Robert parke JM, et al. Antigen-antibody interaction J Biol Chem, 1988; 263(24): 11768-11775
4 Taub R, Gould RJ, Garsky VM, et al. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibtinogen J Biol Chem, 1989;264(1):259-265
5 Williams WV, Moss D, Kieber-Emmons, et al. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA,1989;86:5537-5541
6 Levi M, Sallberg M, Ullaruden, et al. A complementarily-determining region sythetic peptide acts as a mini antibody and neutralizes human immunodeficiency virus type-1 in vitro. Proc Natl Acad Sci USA, 1993; 90:4374-4378
7 Monfardini C, Kieber-Emmons T, Voet D, et al. Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides.J Biol Chem, 1996;271(6): 2966-2971
8 Williams WV, Kieber-Emmons T, Vonfeld D, et al. Design of bioactive peptides based on antibody hypervariable region structures. J BiolChem,1991;266(8):5182- 5190
9 Rose GD, Gierash LM, Smith JA, et al. Turns in peptides and proteins. ADV Protein Chem,1985;37:l-109
10 Smythe ML, Itzstein MV, et al. Design and synthesis of a biologically active antibody mimic based on antibody-antigen crystal structure. J Am Chem Soc,1994;116:2725-2733
11 O'rourke DM, Greene MI, et al. Immunogic approaches to inhibiting cell surface-residing oncoproteins in human tumor. Immunol Res, 1998; 17/1&2:179-189
12 Takasaki W, Kajino Y, Kajino K, et al. Structure-based design and characteriza-tion of exocyclic peptidomimetics that inhibit TNF α binding to its receptor. Nat Biotech 1997; 15:1266-1270
13 Saragovi HU, Fitzpatrick D, Raktabutr A, et al. Design and synthesis of a mimetic form an antibody complementarity-determining region. science,1991;253:792-794
14 Jackson S, Degrado W, Dwivedi A, et al. Template-constrain cyclic peptides design of high-affinity ligands for GpIIb/IIIa. J Am Chem Soc,1994;116:3220-3230
15 Zhang X, Piatier-Taonneau D, Auffray C, et al. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nat Biotech, 1996; 14:472-475
16 Zhang X, Gaubin M, Briant L, et al. Synthetic exocyclics inhibit binding of human immunodeficiency virus type-1 envelope to CD4 and virus replication in T lymphocytes .Nat Biotech, 1997;15:150-154
17 Saragovi HU, Greene MI, Chrusciel RA, et al. Loops and secondary structure mimetics: development and applications in basic science and rational drug design Bio/Technology, 1992;10:773-778
1 Press OW Pros[erts for the managment of non-Hodgki's lymphomas with monoclond antibodies and immunoconjugates Cancer J Sci Am 1998; 4 (supp12):S19-26
2 Press OW, Radiolabeled antibody therapy of B-cell lymphoma. Seminars in Oncology 1999; 26(5): Suppl 14:58-65
3 Tedder TF, Streuli M, Schlossman SF el al. Isolation and structure of a cDNA encoding the BI(CD20) cell-surface antigen of human B lympho cytes.Pro.Natl.Acad.Sci USA 1988;85:208-12
4 Einfeld DA, Brown JP, Valentine MA et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J1988; 7:711-7
5 Stamenkovix I, Seed B. et al. Analysis of two cDNA clones encoding the B lympocyte antigen CD20(B1,Bp35). a type Ⅲ intergral membrane protein. J Exp.Med 1988; 167:1975-80
6 Tedder TF, Disteche CM, Louie E et al. J Immunol 1988; 141:4388-4394
7 Tedder TF, Disteche CM, Louie E et al. J Immunol 1989; 142:2555-2559
8 Tedder TF, Engel P et al. CD20:a regulator of cell cycle progression of B lymphoeytes. Immunol Today 1994; 15(9): 450-454
9 Smeland E, Godal T, Rudd E et al. Proc Natl Acad Sci USA 1985; 82:6255-6259
10 Golay J, Cusmano G, Introna M et al. J Immunol 1992; 149:300-308
11 White MW, McConnell F, Shu GL el al. J Immunol 1991; 146:846-853
12 Clark EA, Shu G et al. J Immunol 1987; 138:720-725
13 Golay JT, Clark EA, Beverley PC, et al. The CD_(20) (Bp35) antigen is involved in activation of B cell from the G_0 to theG_1 phase of the cell cycle. J Immunol. 1985; 135:379514 Bubien JK, Zhou LJ, Bell PD, et al. Transfection of the CD_(20) cell surface molecule into Ectopic cell types Generates a Ca~(2+)conductance Found Constitutively in B Lymphocytes. J. cell Biol. 1993,121(5): 1121-1132
15 Stashenko p., Nsdler LM, Hardy R, et al.J.Immun.1980;125:1678-1685
16 Nadler LM, Karsmeyer SJ, Anderson KC, et al. J.Clin.Invest.1984;74:332-340
17 Stashenko p., Nsdler LM, Hardy R, et al. Proc.Natl.Acad.Sci.USA 1981;78:3848-3852
18 Rosenthal P, Rimm IJ, Umiel T, et al.J.Immunol. 1983; 131:232-237
19 Liu AY, Robinson RJr, Murvay ED, et al. Production of a mouse-human chimeric monoclonal antibody to CD_(20) with potent Fc-dependent biologic activity. J. Immunol. 1987; 139:3521
20 Einleld DA, BrowrmJP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobie protein with multiple transmembrane domains. EMBOJ .1988;7:711
21 Press OW, Farr AG, Borroz KI et al. Endocytosis and degradation of monoclonal antibodies targeting humen B-cell malignancies. Cancer Res 1989; 49:4906-12
22 Press OW, Howell-Clark J, Andereson S et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83:1390-7
23 Liu AY, Robinson R Jr, Murvay ED, et al. Production of a mouse-human chimeric monoclonal antibody to CD_(20) with potent Fc-dependent biologic activity.J.Immunol. 1987; 139:3521
24 Tedder TF et al. Eur J Immunol. 1986;16:881
25 Reff ME, Carner K, Chambers KS et al. Depletion of Bcell in vivo by a chimeric mouse human monoclona antibody to CD20. Blood 1994;83: 435-45
26 杨希峰、沈得诚、金宇光等。HI_(47)：一种抗成熟B细胞单克隆抗体制备、鉴定及其生物学特性研究；上海免疫学杂志，1990；10(2)：65-68
27 Beiske H, Clark EA, Holte H et al. Triggering of neoplastic Bcells via surface IgM and the cell surface antigen CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphotogic subsets. Int J Cancer 1988; 42:521-528
28 Daming Shan, Jeffrey A Ledhetter, Press OW et al. Apoptosis of malignane human B cell by ligation of CD20 with monoclonal antibodies. Blood 1998; 91(5): 1644-1652
29 Press OW, Appelbaum F ledbetter JA et al. Monoclonal antibody IF5(Anti-CD20) serptherapy of human B cell lymphomas. Blood 1987; 69(2): 584-591
30 Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Radiopharmaceuticals 1997 12(3):177 C186.
31 Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8(Rituxan) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-9532 Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma, a multicenter phase Ⅱ study. Blood 1998; 92:1927-32
33 Nguyen DT, Amess JA, Doughty H et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkins lymphoma and lymphoproliferative disorders: evaluation of response on 48 ptients. Eur J Haematol 1999; 62:76-82
34 Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgki's lymphoma. Ann Oncol 1998; 9:995-1001
35 Czuczman MS, Grillo-Lopez AS, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-76
36 Witzig T, White C, Wiseman G et al. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly (abstract). Blood I998; 92:417
37 Flinn IW, O'Ponnell P, Noga SJ et al. In vitro purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL(abstract). Blood 1998; 92:648
38 Vose J, Lister A, Rohatiner A et al. Iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma:overall clinical trial experience(abstract) Am Soc Clin Oncol Proc 1998; 17:10
39 Kaminski MS, Gribbin T, Estes J et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma: clinical and molecular remissions(abstract) Am Soc Clin Oncol Proc 1998; 17:2
40 Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with I-131 labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270-8
41 Hooijberg E, Berk PCM, Sein JJ et al. Enhanced antiumor effects of CD20 over CD 19 monoclonal antibody in a nude mouse xenograft model. Cancer Res 1995; 55:840-846
42 Hooijberg E, Berk PCM, Sein JJ et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995; 55:2627-2634
43 杨希峰、沈得诚、陈璋等。HI_(47)(CD_(20)单克隆抗体对B细胞活化增殖的影响；中国免疫学杂志，1991；7(1)：21-24
44 Weiden P, Breitz H, Press O et al. Radioimmunotherapy(RIT)in the treatment of non-Hodgkin's lymphoma: advantage of pretargeted RIT(abstract). Blood 1998;92:414
45 Jensen M, Tan G, Forman S et al. CD20 is a molecular target for ScFv Fc:zeta receptor redirected Tcells implications for cellular immunotherapy of CD20+malignancy. Biol Blood Marrow Transplant 1998; 4:75-83